文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

按COVID-19疫苗接种状态和既往COVID-19诊断划分的COVID-19病例和住院情况——加利福尼亚州和纽约州,2021年5月至11月

COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2022-01-28

分析加州和纽约州2021年5月至11月成人数据,比较未接种无既往诊断、接种无既往诊断、未接种有既往诊断、接种有既往诊断四组人群的COVID-19发病率和住院率。结果显示接种和既往感染均降低发病和住院风险,Delta变异株成为优势株后既往感染保护作用更高;作者建议所有符合条件者及时接种疫苗。

要点

  • 与未接种无既往诊断者相比,接种无既往诊断者COVID-19病例率在2021年5月30日当周低19.9倍(加州)和18.4倍(纽约)。
  • Delta变异株成为优势株后,有既往诊断者(无论是否接种)病例率大幅降低,如接种有既往诊断者低32.5倍(加州)和19.8倍(纽约)。
  • 加州住院率变化模式与病例率相似;作者建议所有符合条件者及时接种COVID-19疫苗。

核心结论

  • 接种疫苗可预防COVID-19及相关住院,既往感染存活可预防再感染及相关住院。
  • Delta变异株成为优势株后,感染诱导的保护更高,此时许多人的疫苗诱导免疫因免疫逃逸和免疫减弱而下降。
  • 随着包括Omicron在内的新变异株传播,需评估纳入加强针的类似队列数据。
  • 尽管COVID-19流行病学可能随新变异株出现而变化,接种疫苗仍是预防SARS-CoV-2感染及相关并发症的最安全策略;所有符合条件者应及时接种COVID-19疫苗。
  • 随着病毒和免疫水平变化,未来可能需要额外的疫苗剂量建议。

研究设计与样本

  • 分析加州和纽约州全州检测、监测和COVID-19免疫数据,考察初次COVID-19疫苗接种和既往SARS-CoV-2感染对COVID-19发病率和住院率的影响。
  • 考虑四组≥18岁成人队列:未接种且无既往实验室确诊COVID-19诊断、接种(完成初次COVID-19疫苗接种系列后14天)且无既往COVID-19诊断、未接种且有既往COVID-19诊断、接种且有既往COVID-19诊断。
  • 比较两州队列间实验室确诊COVID-19病例的年龄调整风险率,并在加州比较2021年5月30日至11月20日期间的住院情况。

主要发现

  • 研究期间两州COVID-19发病率在未接种且无既往COVID-19诊断者中最高。
  • 2021年5月30日当周,与未接种无既往诊断者相比,接种无既往诊断者COVID-19病例率低19.9倍(加州)和18.4倍(纽约),未接种有既往诊断者低7.2倍(加州)和9.9倍(纽约),接种有既往诊断者低9.6倍(加州)和8.5倍(纽约)。
  • 同期加州住院率与未接种无既往诊断者相比遵循相似模式。
  • 2021年10月3日当周,与未接种无既往诊断者相比,接种无既往诊断者病例率低6.2倍(加州)和4.5倍(纽约),未接种有既往诊断者低29.0倍(加州)和14.7倍(纽约),接种有既往诊断者低32.5倍(加州)和19.8倍(纽约)。
  • 同期加州住院率与未接种无既往诊断者相比遵循相似模式。

临床怎么用

  • 作者结论指出接种疫苗可预防COVID-19及相关住院,既往感染存活可预防再感染及相关住院。
  • 作者建议所有符合条件者应及时接种COVID-19疫苗。
  • 作者认为随着病毒和免疫水平变化,未来可能需要额外的疫苗剂量建议。

局限性

  • 需评估纳入加强针的类似队列数据,因为包括Omicron在内的新变异株在传播。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

By November 30, 2021, approximately 130,781 COVID-19-associated deaths, one in six of all U.S. deaths from COVID-19, had occurred in California and New York.* COVID-19 vaccination protects against infection with SARS-CoV-2 (the virus that causes COVID-19), associated severe illness, and death (1,2); among those who survive, previous SARS-CoV-2 infection also confers protection against severe outcomes in the event of reinfection (3,4). The relative magnitude and duration of infection- and vaccine-derived protection, alone and together, can guide public health planning and epidemic forecasting. To examine the impact of primary COVID-19 vaccination and previous SARS-CoV-2 infection on COVID-19 incidence and hospitalization rates, statewide testing, surveillance, and COVID-19 immunization data from California and New York (which account for 18% of the U.S. population) were analyzed. Four cohorts of adults aged ≥18 years were considered: persons who were 1) unvaccinated with no previous laboratory-confirmed COVID-19 diagnosis, 2) vaccinated (14 days after completion of a primary COVID-19 vaccination series) with no previous COVID-19 diagnosis, 3) unvaccinated with a previous COVID-19 diagnosis, and 4) vaccinated with a previous COVID-19 diagnosis. Age-adjusted hazard rates of incident laboratory-confirmed COVID-19 cases in both states were compared among cohorts, and in California, hospitalizations during May 30-November 20, 2021, were also compared. During the study period, COVID-19 incidence in both states was highest among unvaccinated persons without a previous COVID-19 diagnosis compared with that among the other three groups. During the week beginning May 30, 2021, compared with COVID-19 case rates among unvaccinated persons without a previous COVID-19 diagnosis, COVID-19 case rates were 19.9-fold (California) and 18.4-fold (New York) lower among vaccinated persons without a previous diagnosis; 7.2-fold (California) and 9.9-fold lower (New York) among unvaccinated persons with a previous COVID-19 diagnosis; and 9.6-fold (California) and 8.5-fold lower (New York) among vaccinated persons with a previous COVID-19 diagnosis. During the same period, compared with hospitalization rates among unvaccinated persons without a previous COVID-19 diagnosis, hospitalization rates in California followed a similar pattern. These relationships changed after the SARS-CoV-2 Delta variant became predominant (i.e., accounted for >50% of sequenced isolates) in late June and July. By the week beginning October 3, compared with COVID-19 cases rates among unvaccinated persons without a previous COVID-19 diagnosis, case rates among vaccinated persons without a previous COVID-19 diagnosis were 6.2-fold (California) and 4.5-fold (New York) lower; rates were substantially lower among both groups with previous COVID-19 diagnoses, including 29.0-fold (California) and 14.7-fold lower (New York) among unvaccinated persons with a previous diagnosis, and 32.5-fold (California) and 19.8-fold lower (New York) among vaccinated persons with a previous diagnosis of COVID-19. During the same period, compared with hospitalization rates among unvaccinated persons without a previous COVID-19 diagnosis, hospitalization rates in California followed a similar pattern. These results demonstrate that vaccination protects against COVID-19 and related hospitalization, and that surviving a previous infection protects against a reinfection and related hospitalization. Importantly, infection-derived protection was higher after the Delta variant became predominant, a time when vaccine-induced immunity for many persons declined because of immune evasion and immunologic waning (2,5,6). Similar cohort data accounting for booster doses needs to be assessed, as new variants, including Omicron, circulate. Although the epidemiology of COVID-19 might change with the emergence of new variants, vaccination remains the safest strategy to prevent SARS-CoV-2 infections and associated complications; all eligible persons should be up to date with COVID-19 vaccination. Additional recommendations for vaccine doses might be warranted in the future as the virus and immunity levels change.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. León TM, Dorabawila V, Nelson L, et al. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35085222. doi:10.15585/mmwr.mm7104e1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。